Topic resource collection
Approved comparison material connected to this topic.
774 resourcesRead both sides
BPC-157 Angiogenesis via VEGF upregulation + fibroblast migration Proliferative (days 3–10) 200–500mcg per application Subcutaneous injection near wound site 2–8°C for 28 days (bacteriostatic water) TB-500 (Thymosin Beta-4) Actin…
| Peptide | Primary Mechanism | Injury Type Target | Typical Dose Range | Administration Frequency | Evidence Strength | Professional Assessment ||—|—|—|—|—|—|| BPC-157 | VEGF-mediated angiogenesis, tendon-to-bone healing | Ligam…
Ipamorelin (GH Secretagogue) Ghrelin receptor agonist → endogenous GH pulse → IGF-1 → hormone-sensitive lipase activation Lipolysis, lean mass preservation, protein synthesis 200–300 mcg SC nightly pre-sleep Individuals with low-…
The table below compares intranasal vs subcutaneous anxiolytic peptide protocols based on administration complexity, onset time, and dosing precision requirements. Selank Intranasal 300–900 mcg/day 15–30 minutes No (pre-mixed) Fa…
Before selecting peptides for IBD research protocols, understanding their distinct mechanisms, administration routes, and evidence quality clarifies which compound fits specific research goals. BPC-157 VEGF upregulation, FAK phos…
CJC-1295/Ipamorelin GH secretagogue. Increases lipolysis via HSL activation Moderate (visceral adipocytes express 40% more GH receptors than subcutaneous) Weekly (CJC) + daily (Ipamorelin) 12.3% visceral fat reduction at 24 weeks…
GLP-1 Agonists (semaglutide, tirzepatide) Appetite suppression via hypothalamic GLP-1 receptor activation + delayed gastric emptying Reduced caloric intake (20–30% deficit) STEP-1: 14.9% weight loss at 68 weeks; SURMOUNT-1: 20.9%…
Neuroinflammatory brain fog worsens after infections, correlates with inflammatory flares, and often improves temporarily with anti-inflammatory interventions (curcumin, omega-3s, low-histamine diets). Mitochondrial brain fog wor…
BPC-157 VEGF upregulation → angiogenesis at injury sites; promotes fibroblast migration and collagen synthesis Subcutaneous injection (daily) 200–500mcg/day for 4–8 weeks Symptomatic pain reduction: 7–14 days; structural healing …
Before starting any peptide protocol, understand the trade-offs between compounds, administration routes, and dosing schedules. KPV NF-κB inhibition, cytokine suppression (TNF-α, IL-6) IBS-D, IBS-M 500 mcg/day Once daily (morning…
Cerebrolysin Neurotrophic support (NGF/BDNF mimetic) 5–10 mL daily IM/SC 10–20 days on, 2–4 weeks off Neurotrophic deficiency, age-related decline Gold standard for neurotrophic restoration. Robust clinical data, expensive Dihexa…
| Peptide Class | Primary Mechanism | Standard Dose | Injection Frequency | Cycle Length | Key Co-Factors | Bottom Line ||—|—|—|—|—|—|| TB-500 | Angiogenesis (VEGF upregulation, capillary formation) | 2.5–5mg | 2× weekly loading,…
Cerebrolysin BDNF-like neurotrophic signaling Synaptic plasticity, dendritic arborisation Improved cognitive flexibility, working memory retention 10–30 mL IV daily (clinical); 1–5 mg/kg subcutaneous (research) Strongest evidence…
The table below compares three validated peptide categories used in metabolic research protocols. Each operates through distinct mechanisms and timelines. Growth Hormone Secretagogues (MK 677, CJC-1295) Bind to ghrelin receptors …
BPC-157 Tight junction repair, VEGF upregulation, mucosal healing IBS-D (diarrhea-predominant) 250–500 mcg subcutaneous twice daily Bacteriostatic water, 2–8°C storage, use within 28 days First-line for barrier dysfunction. Addre…
Cerebrolysin BDNF/NGF receptor agonism via multi-peptide mixture Requires IV/IM. Does not passively cross BBB 2.5–5 mL IM (scaled by weight) 4–6 hours Intramuscular or intravenous Best for protocols requiring broad neurotrophic s…
Before selecting a peptide protocol, understanding the mechanistic differences between the primary candidates clarifies which approach aligns with the specific pathology. BPC-157 VEGF upregulation, IL-6 suppression, collagen synt…
BPC-157 (Body Protection Compound) Stimulates VEGF and fibroblast proliferation; accelerates collagen type I deposition in tendons 250–500mcg daily, 4–6 weeks Subcutaneous, upper deltoid or arm within 5–8cm of injury Most evidenc…
Selank GABA-A receptor upregulation Panic disorder, acute episodic anxiety 600mcg–2.4mg/day intranasal or subcutaneous 10–14 days Multiple RCTs, moderate-quality evidence Semax BDNF elevation, neuroprotection GAD, chronic stress-…
Systemic Autoimmunity (Lupus, RA, MS) Thymalin Thymic regeneration and Treg expansion via thymulin secretion 5–10mg subcutaneous twice weekly 8–12 weeks for measurable Treg increase, 16–24 weeks for symptom reduction Best for mul…